143 related articles for article (PubMed ID: 18581593)
1. Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients.
Lee HK; Chae HS; Kim JS; Kim HK; Cho YS; Rho SY; Kang JH; Cho SG; Jang HS; Han K
Yonsei Med J; 2008 Jun; 49(3):429-35. PubMed ID: 18581593
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of vascular endothelial growth factor in malignant ascites.
Zhan N; Dong WG; Wang J
Tumour Biol; 2016 Mar; 37(3):3719-25. PubMed ID: 26462841
[TBL] [Abstract][Full Text] [Related]
3. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
Zhu FL; Ling AS; Wei Q; Ma J; Lu G
Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
[TBL] [Abstract][Full Text] [Related]
4. Role of VEGF and CD44v6 in differentiating benign from malignant ascites.
Dong WG; Sun XM; Yu BP; Luo HS; Yu JP
World J Gastroenterol; 2003 Nov; 9(11):2596-600. PubMed ID: 14606105
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant ascites.
Nascimento I; Schaer R; Lemaire D; Freire S; Paule B; Carvalho S; Meyer R; Schaer-Barbosa H
APMIS; 2004 Sep; 112(9):585-7. PubMed ID: 15601306
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.
Cheng D; Liang B; Kong H
Med Oncol; 2012 Jun; 29(2):1397-402. PubMed ID: 21556933
[TBL] [Abstract][Full Text] [Related]
7. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation.
Kaleta EJ; Tolan NV; Ness KA; O'Kane D; Algeciras-Schimnich A
Clin Biochem; 2013 Jun; 46(9):814-8. PubMed ID: 23454392
[TBL] [Abstract][Full Text] [Related]
8. Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Findeisen R; Albrecht S; Richter B; Deutschmann K; Zimmermann T; Distler W
Luminescence; 2000; 15(5):283-9. PubMed ID: 11038485
[TBL] [Abstract][Full Text] [Related]
9. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
[TBL] [Abstract][Full Text] [Related]
10. Value of
Han N; Sun X; Qin C; Hassan Bakari K; Wu Z; Zhang Y; Lan X
AJR Am J Roentgenol; 2018 May; 210(5):1155-1163. PubMed ID: 29629798
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.
Liu F; Kong X; Dou Q; Ye J; Xu D; Shang H; Xu K; Song Y
Ann Hepatol; 2014; 13(3):357-63. PubMed ID: 24756011
[TBL] [Abstract][Full Text] [Related]
12. A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.
Abdel-Razik A; Mousa N; Elalfy H; Sheta TF; Awad M; Abdelsalam M; Elhelaly R; Elzehery R; Gouda NS; Eldars W
J Gastrointest Cancer; 2017 Mar; 48(1):50-57. PubMed ID: 27614744
[TBL] [Abstract][Full Text] [Related]
13. Markedly elevated levels of vascular endothelial growth factor in malignant ascites.
Zebrowski BK; Liu W; Ramirez K; Akagi Y; Mills GB; Ellis LM
Ann Surg Oncol; 1999 Jun; 6(4):373-8. PubMed ID: 10379858
[TBL] [Abstract][Full Text] [Related]
14. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation.
Verheul HM; Hoekman K; Jorna AS; Smit EF; Pinedo HM
Oncologist; 2000; 5 Suppl 1():45-50. PubMed ID: 10804091
[TBL] [Abstract][Full Text] [Related]
15. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer.
Cooper BC; Ritchie JM; Broghammer CL; Coffin J; Sorosky JI; Buller RE; Hendrix MJ; Sood AK
Clin Cancer Res; 2002 Oct; 8(10):3193-7. PubMed ID: 12374688
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of tumor markers for lung adenocarcinoma-associated malignant pleural effusion: a validation study and meta-analysis.
Feng M; Zhu J; Liang L; Zeng N; Wu Y; Wan C; Shen Y; Wen F
Int J Clin Oncol; 2017 Apr; 22(2):283-290. PubMed ID: 27990560
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
Rudlowski C; Pickart AK; Fuhljahn C; Friepoertner T; Schlehe B; Biesterfeld S; Schroeder W
Int J Gynecol Cancer; 2006; 16 Suppl 1():183-9. PubMed ID: 16515588
[TBL] [Abstract][Full Text] [Related]
18. [Clinical significance of detecting VEGF, CD44v6, MMP-2, and MMP-9 in malignant ascites].
Sun XM; Dong WG; Yu BP; Luo HS; Yu JP
Ai Zheng; 2004 Jan; 23(1):85-9. PubMed ID: 14720382
[TBL] [Abstract][Full Text] [Related]
19. Ascites metabolism measurement enhanced the diagnostic value and accuracy of prognostic evaluation in 18F-FDG PET/CT studies in malignant ascites patients.
Li XJ; Li FQ; Han JK; Zhao ZH; Song ZG; Dai XZ
Nucl Med Commun; 2013 Jun; 34(6):544-50. PubMed ID: 23511926
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
